Future studies will incorporate companion diagnostics during the course of clinical development in order to identify patient populations who express the antigen recognized by NEO-201 and are most likely to benefit from this potential therapeutic agent targeting tumor-specific variants of CEACAM-5 and CEACAM-6. The gene discussed is CEACAM6; the disease is neoplasm.